There is a big concerted effort to keep it down. All the prongs are aligned to the attack.
It happens to every successful small cap. I wish the SEC had the manpower to prosecute this practice.
If you take out insider[28%] and institutional ownership[50%], it makes a squeeze even more likely.
The price will settle to fair value eventually with or without a short squeeze. I just like to see the squeeze for the arrogant shorts' anguish. I think they should tenaciously maintain their short position for three more quarterly reports.
All of those points mentioned implies the guts and genius of the Zogenix scientists and funders and many of the stockholders who stuck with it for the last few years. This is 25% insider owned and their payday is arriving.
I wonder what their next big move will be.
This is a five year hold.
The reschedule is probably why approval took so long.
The gubmint did something right here, as professionals with pride in their work will do on occasion.
and an update on how the products are moving.
I expect to see a modest uptick in dosepro with all the extra reps pushing it too. Right now I think Sumavel Dosepro has about 50million per year sales? If they cross the high teens for the quarter that is a good sign.
It looks to be an effectivly fair system. Only 900k shares to incentivize a billion+ in sales over the next three years is good use of capital.
Trade common shares for a while before you get into options, and if you do options, go significantly in-the-money on a dip.
Naw stay away from options until you feel more confident.
Twosmallgems gave reasonable ideas.
Pharmaceutical issues can be tricky. Zog is less speculative than others.
someone here said that someone else here said it is going to zero.
You're right, they should hold their short position until then.
nice little bonus opportunity by the shorts yesterday in the low 4's. They will have to cover the shares they shorted to me in the high 6's
Screw abuse deterancy. It compromises efficacy and it is useless pharmacologically speaking. Quite useful, politically speaking however.